Zacks: Enzymotec Ltd. (ENZY) Receives Average Rating of “Hold” from Analysts
Shares of Enzymotec Ltd. (NASDAQ:ENZY) have earned a consensus broker rating score of 3.33 (Hold) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a sell recommendation and two have assigned a hold recommendation to the company.
Analysts have set a 12 month consensus price target of $9.33 for the company and are anticipating that the company will post $0.10 EPS for the current quarter, according to Zacks. Zacks has also assigned Enzymotec an industry rank of 175 out of 265 based on the ratings given to related companies.
A number of research analysts have recently commented on the company. ValuEngine upgraded Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research cut Enzymotec from a “hold” rating to a “sell” rating in a research note on Monday, May 22nd.
A number of hedge funds and other institutional investors have recently made changes to their positions in ENZY. Acadian Asset Management LLC raised its position in shares of Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock valued at $2,088,000 after buying an additional 7,322 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 3,113 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Enzymotec during the second quarter valued at about $2,350,000. Finally, State Street Corp raised its position in shares of Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 380 shares in the last quarter. 27.92% of the stock is owned by institutional investors and hedge funds.
Shares of Enzymotec (NASDAQ:ENZY) traded down 0.44% during trading on Friday, hitting $11.40. 45,564 shares of the stock were exchanged. The stock’s market cap is $261.62 million. The stock’s 50 day moving average price is $8.98 and its 200 day moving average price is $8.65. Enzymotec has a one year low of $5.20 and a one year high of $12.35.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of $0.05 by $0.15. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm had revenue of $13 million during the quarter, compared to the consensus estimate of $12.78 million. During the same quarter in the previous year, the company posted $0.04 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. Equities research analysts predict that Enzymotec will post $0.14 EPS for the current year.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.